Data Bridge Market Research has recently added concise research on the Obsessive-Compulsive Disorder (OCD) Drugs Market report to depict valuable insights related to significant market trends driving the industry. The Global Obsessive-Compulsive Disorder (OCD) Drugs Market report makes available the basic information about industry, definition, classification, application, industry chain structure, industry overview and international market analysis.

Global Obsessive-Compulsive Disorder (OCD) Drugs Market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 9.7% in the forecast period of 2021 to 2028 and is expected to reach USD 996.90 million by 2028. Rise in clinical trials and increasing R&D investment by market players are the major drivers which propelled the demand of the market in the forecast period.

Obsessive-compulsive disorder (OCD) refers to an anxiety disorder that is characterized by unreasonable and uncontrollable thoughts and fears leading an individual to perform repetitive behaviours. Obsessive-compulsive disorder is a disorder known to compel a person to get stuck on a particular thought or fear. The developments in the treatment, therapies and novel treatment, and advancements in the anti-anxiety, antipsychotic and antidepressant drugs is expected to provide various other opportunities in the OCD drugs market. However, patent expiry of the patented drugs and introduction of generic version of branded drugs are factors expected to restraint the market growth in the forecast period.

In August 2020, Sun Pharmaceutical Industries Limited announced that it had launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet for the treatment of mild to moderate cases of COVID-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease. The company is launching FluGuard at an economical price to make the drug accessible to more and more patients, thereby reducing their financial burden. This has supported India’s pandemic response.

In April 2021, H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce the decision to continue recruiting patients in phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type (NCT03548584). The continuation of the study enables Lundbeck and Otsuka to explore further the efficacy of brexpiprazole to address the high medical need in patients suffering from agitation in Alzheimer’s type dementia. The completion of the trial successfully will result in a new product launch, thus impacting the sales and revenue of the company.

In June 2021, Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the U.S. launch of its generic version once-daily SOOLANTRA (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea. With launch of products, Teva has become a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area.

Table of Contents:

Global Obsessive-Compulsive Disorder (OCD) Drugs Market Overview
Economic Impact on Industry
Competition by Manufacturers
Production, Revenue (Value) by Region
Supply (Production), Consumption, Export, Import by Regions
Production, Revenue (Value), Price Trend by Type
Market by Application
Manufacturing Cost Analysis
Industrial Chain, Sourcing Strategy and Downstream Buyers
Marketing Strategy Analysis, Distributors/Traders
Market Effect Factors Analysis
Market Forecast
Appendix

List of Figures:

Figure 1 Global Obsessive-Compulsive Disorder (OCD) Drugs Market: Segmentation

Figure 2 Global Obsessive-Compulsive Disorder (OCD) Drugs Market: Data Triangulation

Figure 3 Global Obsessive-Compulsive Disorder (OCD) Drugs Market: Droc Analysis

Figure 4 Global Obsessive-Compulsive Disorder (OCD) Drugs Market: Global Vs Regional Market Analysis

Figure 5 Global Obsessive-Compulsive Disorder (OCD) Drugs Market: Company Research Analysis

Figure 6 Global Obsessive-Compulsive Disorder (OCD) Drugs Market: Interview Demographics

Figure 7 Global Obsessive-Compulsive Disorder (OCD) Drugs Market: DBMR Market Position Grid

Figure 8 Global Obsessive-Compulsive Disorder (OCD) Drugs Market: Vendor Share Analysis

Figure 9 Global Obsessive-Compulsive Disorder (OCD) Drugs market: Segmentation

Figure 10 North America Is Expected to Dominate and Asia-Pacific Is the Fastest Growing Region in the Global Obsessive-Compulsive Disorder (OCD) Drugs Market in the Forecast To 2028

Continued...

The Obsessive-Compulsive Disorder (OCD) Drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Obsessive-Compulsive Disorder (OCD) Drugs market.

The major companies operating in the global obsessive-compulsive disorder (OCD) drugs market are Abbott, Eli Lilly, and Company, Viatria Inc., H. LUNDBECK A/S, GlaxoSmithKline plc., Pfizer Inc., Mallinckrodt, Sebela Pharmaceuticals, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Lupin Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical industries Ltd., Wockhardt, Alvogen, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), Par Pharmaceutical, Apotex Inc., Lannett, among others.